Man of Steel Syndrome: Silicone and Mineral Oil Injections With Associated Hypercalcemia, Hypophosphatemia, and Proximal Muscle Weakness

Silicone/mineral oil‐induced granulomas have been described as an inflammatory granulomatous response when silicone/mineral oil is injected for cosmetic purposes. These sclerosing granulomas can lead to hypercalcemia. Here we present a 33‐year‐old man with hypercalcemia, hypophosphatemia, progressively worsening fatigue, severe proximal muscle weakness, and depression. He had an athletic build with increased muscle bulk and several areas of indurated, nontender, firm, well‐circumscribed lesions in the subcutaneous tissue of his anterior pectoralis, triceps, and biceps bilaterally because of injecting himself with silicone/mineral oil‐based product into his muscles. Sclerosing granulomas were diagnosed on the MRI. He had extremely low or undetectable serum levels of 25‐hydroxyvitamin D [25(OH)D], and persistently elevated serum levels of 1,25‐dihydroxyvitamin D [1,25(OH)2D] and calcium. He developed hypophosphatemia associated with elevated levels of fibroblast growth factor 23 (FGF‐23) and severe proximal muscle weakness. Treatment with systemic steroids, furosemide, calcitonin, ketoconazole, and denosumab resulted in a significant decrease in his serum calcium, but with minimal impact on his hypophosphatemia and fatigue.Correcting his severe vitamin D deficiency with small doses of vitamin D and raising his blood level of 25(OH)D from undetectable to 10 ng/mL without significantly affecting his serum calcium or phosphate was effective in reversing his severe proximal muscle weakness, permitting him to lift his head and to be free of his wheelchair. Although measurement of the 1,25(OH)2D level is not mandatory in all cases of hypercalcemia, it is indicated in a patient who has low serum PTH levels. Clinicians need to be aware that vitamin D deficiency can cause severe proximal muscle weakness such that the patient is unable to lift his head from his chest or ambulate. This may lead to a psychiatric disorder misdiagnosis. © 2019 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.

[1]  M. Inaba,et al.  Fibroblast Growth Factor-23 and Vitamin D Metabolism in Subjects with eGFR ≥60 ml/min/1.73 m2 , 2015, Nephron.

[2]  P. Sethi,et al.  Severe Vitamin D Deficiency Induced Myopathy Associated with Rhabydomyolysis , 2013, North American journal of medical sciences.

[3]  M. Holick,et al.  Hypercalcemia associated with mineral oil-induced sclerosing paraffinomas. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  M. Dharmalingam,et al.  Vitamin D deficiency presenting like hypophosphatemic osteomalacia , 2012, Indian journal of endocrinology and metabolism.

[5]  G. Bedogni,et al.  Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws? , 2012, The oncologist.

[6]  Charles Chan,et al.  A case of severe 1,25-dihydroxyvitamin D-mediated hypercalcemia due to a granulomatous disorder. , 2012, The Journal of clinical endocrinology and metabolism.

[7]  M. Econs,et al.  Approach to the hypophosphatemic patient. , 2012, The Journal of clinical endocrinology and metabolism.

[8]  F. Pellicciotti,et al.  Challenges in the differential diagnosis of hypercalcemia: A case of hypercalcemia with normal PTH level. , 2012, World journal of clinical oncology.

[9]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[10]  T. Sakaguchi,et al.  Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. , 2010, American journal of physiology. Renal physiology.

[11]  Phillip K Pellitteri,et al.  Evaluation of hypercalcemia in relation to hyperparathyroidism. , 2010, Otolaryngologic clinics of North America.

[12]  J. Buckley,et al.  Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. , 2010, Respiratory medicine.

[13]  A. Pick,et al.  1,25-Dihydroxyvitamin D-mediated hypercalcemia in oleogranulomatous mastitis (paraffinoma), ameliorated by glucocorticoid administration. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[14]  M. Jan,et al.  Severe Proximal Myopathy with Remarkable Recovery after Vitamin D Treatment , 2009, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  H. Tenenhouse,et al.  Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. , 2007, American journal of physiology. Renal physiology.

[16]  M. Leow,et al.  Calcinosis cutis with siliconomas complicated by hypercalcemia. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[17]  F. Hu,et al.  Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. , 2004, The American journal of clinical nutrition.

[18]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  S. Dagogo-Jack,et al.  Reversible muscle weakness in patients with vitamin D deficiency. , 1997, The Western journal of medicine.

[20]  A. Barbato,et al.  Hypercalcemia associated with silicone-induced granulomas. , 1984, The New England journal of medicine.